KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Cash from Investing Activities Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -78.48%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -32.26%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -4.78%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -62.97%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -36.21%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 60.61%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -38.13%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 14.56%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 14.56%
Dec 31, 2025 -47.39%
Sep 30, 2025 6.48%
Jun 30, 2025 -17.85%
Mar 31, 2025 -93.57%
Dec 31, 2024 -35.52%
Sep 30, 2024 39.23%
Jun 30, 2024 -110.50%
Mar 31, 2024 -415.75%
Dec 31, 2023 51.52%
Sep 30, 2023 -24.39%
Jun 30, 2023 -37.36%
Mar 31, 2023 -32.84%
Dec 31, 2022 28.05%
Sep 30, 2022 -84.09%
Jun 30, 2022 -33.96%
Mar 31, 2022 -55.25%
Dec 31, 2021 31.51%
Sep 30, 2021 -87.95%
Jun 30, 2021 36.03%
Mar 31, 2021 -49.26%
Dec 31, 2020 -138.65%
Sep 30, 2020 -51.83%
Jun 30, 2020 36.49%
Mar 31, 2020 71.05%
Dec 31, 2019 -813.85%
Sep 30, 2019 49.39%
Jun 30, 2019 20.76%
Mar 31, 2019 -9.41%
Dec 31, 2018 -14.11%
Sep 30, 2018 -33.34%
Jun 30, 2018 35.22%
Mar 31, 2018 -27.18%
Dec 31, 2017 42.66%
Sep 30, 2017 -4.69%
Jun 30, 2017 12.16%
Mar 31, 2017 -27.89%
Dec 31, 2016 27.05%
Sep 30, 2016 8.16%
Jun 30, 2016 92.41%
Mar 31, 2016 106.90%
Dec 31, 2015 -77.08%
Sep 30, 2015 75.47%
Jun 30, 2015 -97.16%
Mar 31, 2015 31.02%
Dec 31, 2014 -10.83%
Sep 30, 2014 44.32%
Jun 30, 2014 -65.72%
Mar 31, 2014 52.40%
Dec 31, 2013 49.73%
Sep 30, 2013 -35.74%
Jun 30, 2013 -37.90%
Mar 31, 2013 27.32%
Dec 31, 2012 31.42%
Sep 30, 2012 -28.32%